Approximately 33% of all non-small cell lung cancer patients in East Asia are never smokers – a growing and unaddressed patient population.
Dr. Yashushi Goto a leading lung cancer.
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Survivors of childhood cancer are at excess risk of late mortality even 40 years from
diagnosis, due to many of the leading causes of death in the US population. Modifiable
lifestyle and cardiovascular risk factors associated with reduced risk for late mortality
should be part of future interventions.
Combined advances in haematopoietic cell transplantation (HCT) and intensive care
management have improved the survival of patients with haematological malignancies
admitted to the intensive care unit. In cases of refractory respiratory failure or
refractory cardiac failure, these advances have led to a renewed interest in advanced
life support therapies, such as extracorporeal membrane oxygenation (ECMO), previously
considered inappropriate for these patients due to their poor prognosis. Given the
scarcity of evidence-based guidelines on the use of ECMO in patients receiving HCT
and the need to provide equitable and sustainable access to ECMO, the European Society
of Intensive Care Medicine, the Extracorporeal Life Support Organization, and the
International ECMO Network aimed to develop an expert consensus statement on the use
of ECMO in adult patients receiving HCT.
The treatment framework for advanced non-small-cell lung cancer harbouring anaplastic
lymphoma kinase (ALK) fusions has changed substantially since the discovery of crizotinib,
a first-generation ALK tyrosine-kinase inhibitor (TKI). Three generations of ALK TKIs
have since been developed, with increasing potency, CNS penetrance, and ability to
overcome ALK-resistance mutations with each successive generation.1 Multiple phase
3 trials have shown superior efficacy of second-generation ALK TKIs (alectinib, brigatinib,
and ensartinib) compared with crizotinib, establishing next-generation ALK TKIs as
preferred initial therapy.